Treatment for adrenal disorders aims to restore biochemical hormone balance, control systemic cardiovascular and metabolic symptoms, and eliminate malignant or hyperfunctioning tissue. Depending on whether the diagnosis involves hormone hypersecretion (such as Cushing syndrome, primary aldosteronism, or pheochromocytoma) or insufficiency (such as Addison disease), care combines precision hormone suppression, targeted receptor blockade, exogenous hormone replacement, or minimally invasive endocrine surgery.

Diagnostic workup involves baseline hormone measuring, dynamic suppression or stimulation testing, and adrenal protocol CT or MRI. Medical stabilization includes targeted receptor blockers, steroidogenesis inhibitors, or alpha-adrenergic receptor blockade. Surgical procedures utilize transperitoneal laparoscopic, posterior retroperitoneoscopic, or open approaches to resect the affected adrenal gland while preserving surrounding vascular structures. Post-operative management requires hydrocortisone coverage, electrolyte monitoring, and serial hormonal re-evaluation.

Evidence-based treatment for adrenal disorders restores endocrine equilibrium, resolves life-threatening electrolyte imbalances, normalizes refractory hypertension, reduces long-term cardiovascular mortality, mitigates metabolic dysfunction, and eliminates the risk of local invasion or metastasis from adrenal neoplasms.

Recovery timelines vary according to the treatment approach. Surgical recovery following laparoscopic adrenalectomy typically requires an inpatient stay of one to two days, with full resumption of normal physical activities in two to four weeks. Patients initiating medical management or corticosteroid replacement require several weeks of dosage adjustment and regular laboratory follow-up to establish metabolic stability.

Adrenal disorder management addresses primary adrenal insufficiency (Addison disease), secondary and tertiary adrenal insufficiency, endogenous Cushing syndrome, primary aldosteronism (Conn syndrome), pheochromocytoma, adrenocortical carcinoma, congenital adrenal hyperplasia, and functioning or non-functioning adrenal incidentalomas.

Pre-treatment preparation requires exhaustive hormone screening to exclude or confirm pheochromocytoma and hypercortisolism. Patients with pheochromocytoma undergo seven to fourteen days of preoperative alpha-adrenergic blockade followed by beta-blockade to prevent intraoperative hypertensive crises. Patients undergoing adrenalectomy for hypercortisolism receive perioperative stress-dose glucocorticoids to avoid perioperative adrenal insufficiency. Sodium and potassium imbalances are corrected medically before intervention.

Risks include acute primary adrenal crisis, intraoperative severe blood pressure fluctuations, postoperative hemorrhage, deep vein thrombosis, wound infection, damage to adjacent organs such as the spleen, liver, pancreas, or renal vessels, chronic incisional hernia, and persistent or recurrent hormone excess.

The clinical pathway begins with specific biochemical screening and confirmatory dynamic hormone testing, followed by high-resolution cross-sectional imaging to localize structural lesions. Patients with hormone-secreting tumors or suspicious masses undergo specialized pre-operative medical stabilization before undergoing minimally invasive or open surgical resection. Following intervention or initiation of lifelong pharmacotherapy, patients undergo routine endocrine monitoring, medication titrations, and ongoing surveillance to prevent acute complications like adrenal crisis.